Securities code: Boya Bio-Pharmaceutical Group Co.Ltd(300294) securities abbreviation: Boya Bio-Pharmaceutical Group Co.Ltd(300294) Announcement No.: 2022012 Boya Bio-Pharmaceutical Group Co.Ltd(300294) 2021 annual report summary I. important tips
The summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC.
All directors have attended the meeting of the board of directors to consider this report.
The audit opinion of Ernst & Young Huaming Certified Public Accountants (special general partnership) on the company’s financial report this year is: standard unqualified opinion.
Changes of accounting firm during the reporting period: the accounting firm of the company was changed to Ernst & Young Huaming accounting firm (special general partnership) this year.
Prompt of non-standard audit opinion □ applicable √ not applicable
The company is not profitable at the time of listing and is not profitable at present □ applicable √ not applicable
The profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period reviewed by the board of directors √ applicable □ not applicable
The company’s profit distribution plan for ordinary shares reviewed and approved by the board of directors is: taking 504248738 as the base, distribute cash dividend of 1.50 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
Profit distribution plan for preferred shares in the reporting period adopted by the board of directors □ applicable √ not applicable
2、 Basic information of the company 1. Company profile
Stock abbreviation Boya Bio-Pharmaceutical Group Co.Ltd(300294) stock code Boya Bio-Pharmaceutical Group Co.Ltd(300294)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Tu Yanshi Peng dongke
Office address: No. 333, Huiquan Road, high tech Industrial Development Zone, Fuzhou City, Jiangxi Province
Fax: 07948237323
Tel: 643907829439078
E-mail dongmi@china -boya. com. pengdk@china -boya. com.
2. Introduction to main business or products during the reporting period
During the reporting period, the company has always focused on the development strategy of “becoming a world-class blood products enterprise”, adhered to the principle of taking blood products as the leading factor, and actively stabilized the business of non blood products. During the reporting period, the company mainly involved in the blood products business, the diabetes medicine business in Tianan pharmaceutical industry, the biochemical medicine business in Xinbai pharmaceutical industry, the pharmaceutical business in Boya Xinhe and the pharmaceutical distribution business in the general hospital.
1. Blood products business
The company is mainly engaged in the R & D, production and sales of blood products. According to different functions and structures, blood products can be divided into three categories: albumin, immunoglobulin and coagulation factors. Albumin is the most abundant protein in plasma. It is also the largest blood product in China, and is widely used in the treatment of cancer, liver disease and diabetes. Immunoglobulin mainly refers to the original immunoglobulin in the blood and the specific immunoglobulin stimulated by specific immunogens. It is mostly used in the treatment of immune diseases, passive immunity and treatment of infectious diseases, etc; The content of coagulation factor is the least in blood, and coagulation factor products are mainly used for coagulation and hemostasis.
Blood products play an important role in the treatment and prevention of a variety of major diseases, which can not be replaced by other drugs. They are national strategic resources. In terms of blood products, the company is one of the leading manufacturers of blood products in China. Its products cover 8 varieties and 22 specifications, such as human albumin, intravenous human immunoglobulin (pH4) and coagulation factor.
The main products, application fields and functions of the company are as follows:
Application fields and functions of classified varieties
The most abundant protein in plasma accounts for about 60% of plasma protein; It has the functions of regulating plasma osmotic pressure, transportation, detoxification and human albumin nutritional supply; It is suitable for patients with cancer, chemotherapy or radiotherapy, hypoproteinemia, burns, hemorrhagic shock, liver disease and diabetes. It can be used in cardiopulmonary bypass, adjuvant therapy for hemodialysis and adult respiratory distress syndrome.
Human immunoglobulin can prevent measles and infectious hepatitis. If combined with antibiotics, it can improve the curative effect on some bacterial and viral infections.
Intravenous human immunoglobulin has good tolerance to high-dose intravenous injection, and there are many clinical indications. It is suitable for primary immunoglobulin deficiency, secondary immunoglobulin deficiency and autoimmune diseases.
Immunoglobulin lyophilized intravenous injection of human immunoglobulin is suitable for primary immunoglobulin deficiency, secondary immunoglobulin deficiency and autoimmune diseases.
Hepatitis B Human Immunoglobulin is mainly used for passive immunization, treatment and liver transplantation of hepatitis B.
Immunoglobulin of rabies patients is mainly used for passive immunization and treatment of patients bitten and scratched by rabies dogs or other animals carrying rabies virus.
Human fibrinogen is mainly used for congenital or acquired fibrinogen deficiency and disseminated intravascular coagulation; Postpartum hemorrhage and coagulation disorder caused by fibrinogen deficiency caused by major surgery, trauma or internal bleeding.
It is mainly used to treat congenital and acquired deficiency of coagulation factors II, VII, IX and X (single or combined deficiency), including: 1. Deficiency of coagulation factors II, VII, IX and X, including type B hemophilia; 2. Excessive anticoagulants, vitamin K deficiency and human prothrombin complex deficiency; 3. Coagulation mechanism disorder caused by liver disease and bleeding caused by liver disease when patients need to correct coagulation dysfunction; 4. Patients with prothrombin time prolongation due to various reasons and planning surgery, but it may not be effective for patients with coagulation factor V deficiency; 5. Treatment of bleeding symptoms in patients with hemophilia A who have produced factor VIII inhibitor; 6. Reverse coumarin anticoagulant induced bleeding.
During the reporting period, while ensuring the stable supply of raw plasma, the company continuously improved the quality management level, optimized the production process, strengthened the control of the production process, and ensured the stability of product yield and qualification rate. The batch issuance of blood products of the company is as follows:
Total quantity (bottle)
Increase or decrease of product name and specification
2021 (January December) 2020 (January December)
5g / bottle (20%, 25ml) 41003227723947.90%
Human albumin 10g / bottle (20%, 50ml) 83620272704315.01%
12.5g/bottle (25%, 50ml) 12551
1.25g/bottle (5%, 25ml) 12720225954 390.11%
Intravenous injection of human immunoglobulin 2.5g/bottle (5%, 50ml) 331909383239 – 13.39%
5g / bottle (5%, 100ml) 18949812610050.28%
Human prothrombin complex 2.5g/bottle 111830
Human fibrinogen 0.5g/bottle 564497271991107.54%
Rabies patient immunoglobulin 200iu / 2ml / bottle 374681806009 – 53.51%
Hepatitis B human immunoglobulin 200iu / 2ml / bottle 36731
2, Tianan pharmaceutical diabetes medication business
Tianan pharmaceutical is a high-tech enterprise integrating research, production and sales. It is committed to the development, research and production of diabetes and its complications, and is a specialized pharmaceutical company for diabetes drugs in China. At present, the “Tianan brand” series of diabetes products include: A Tami (Glimepiride Tablets), Ando Ming (Calcium Dobesilate Capsules), Ando (metformin hydrochloride enteric coated tablets), anddujian (Pioglitazone Hydrkchloride Dispersible Tablets) and other more than 10 kinds of drugs. Tianan pharmaceutical has formed a strong market competitive advantage in the field of diabetes drug segmentation market. The product line is complete, covering two categories of oral products, such as guanidine, huangurea, glennaide, thiazolidone and four ketones.
The main products, application fields and functions of Tian’an pharmaceutical are as follows:
Varieties, application fields and functions
Metformin hydrochloride tablets / enteric coated tablets can improve insulin sensitivity, which is manifested in the decrease of fasting blood glucose level and insulin level. For patients with type 2 diabetes, diet and exercise therapy fails, especially for obese people, especially when sulfonylureas are not able to control hyperglycemia.
Pioglitazone Hydrkchloride Dispersible Tablets is suitable for patients with type 2 diabetes mellitus (NIDDM). It can be combined with diet control and physical exercise to improve and control blood sugar. It can also be combined with sulfonylurea, metformin or insulin.
Glimepiride Tablets is suitable for controlling diet, exercise therapy and reducing type 2 diabetes.
Calcium dobesilate capsule is suitable for the treatment of microvascular disease, varicose syndrome, venous insufficiency associated with microcirculation disorder, venous stripping and venous sclerosis.
3. Biochemical medicine business of Xinbai pharmaceutical
Jiangsu Province has established a batch of “research and development centers for biochemical drugs” in the field of pharmaceutical research and development, and has established the earliest batch of pharmaceutical research and development centers in the country. After years of development, Xinbai pharmaceutical industry has gradually formed a “biochemical pharmaceutical based, supplemented by chemical drugs; injection based, supplemented by other dosage forms”
